GQG Partners LLC Has $31.72 Million Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

GQG Partners LLC grew its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 359.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,008,759 shares of the company’s stock after purchasing an additional 1,571,808 shares during the quarter. GQG Partners LLC’s holdings in Dr. Reddy’s Laboratories were worth $31,718,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock valued at $29,000 after purchasing an additional 1,507 shares in the last quarter. POM Investment Strategies LLC grew its holdings in shares of Dr. Reddy’s Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after purchasing an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC increased its position in Dr. Reddy’s Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after purchasing an additional 2,093 shares in the last quarter. Allworth Financial LP lifted its stake in Dr. Reddy’s Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after purchasing an additional 2,230 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of Dr. Reddy’s Laboratories during the 4th quarter valued at $43,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY opened at $13.72 on Tuesday. The business’s fifty day moving average is $13.63 and its 200 day moving average is $14.67. Dr. Reddy’s Laboratories Limited has a 12-month low of $12.50 and a 12-month high of $16.89. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The stock has a market cap of $11.45 billion, a P/E ratio of 21.84 and a beta of 0.48.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Sell-side analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.